Lung Cancer Online
Home Care Support Info Treatment Effects Tests Surviving Sites MedLit

 home > treatment > agents & regimens > BEC2

BEC2 (Mitumomab) : ImClone Systems : Monoclonal antibody

Phase III Study of BEC2/BCG Vaccination in Limited SCLC - the SILVA study (ASCO)
Abstract of study reported at the 2004 ASCO annual meeting that found vaccination with BEC2/BCG does not provide any survival advantage in limited SCLC patients after a major response to induction chemo-radiation. [6/04]

BEC2 (ImClone Systems)
Describes BEC2, a monoclonal antibody, currently being studies in small cell lung cancer.

BEC2 - Recent MEDLINE Abstracts (PubMed)

BEC2 - Clinical Trials (ClinicalTrials.com)


 

Feedback / Queries Disclaimer Advocacy - You Can Help

Copyright © 1999-2006, Lung Cancer Online Foundation
Last modified: 18-Feb-2009
Karen Parles, MLS Editor